Gretchen L. Temeles, Ph.D., practices in the area of intellectual property law with a focus on the chemical, biotechnology and pharmaceutical industries. Dr. Temeles assists clients with patent procurement and patent portfolio management. She has experience in patent landscape analyses, freedom-to-operate searches, patent due diligence, and non-infringement and invalidity opinions. She also assists clients with transactional work, including material transfer agreements and sponsored research agreements. Dr. Temeles has worked on patent matters encompassing a wide range of technologies including food processing and food safety, genetic engineering, diagnostics, screening technologies, biologics, vaccines, stem cells, medical devices, probiotics, tissue engineering, pharmaceuticals, transgenic plants and animals, environmental remediation, and biofuels. These matters cover a variety of therapeutic areas including cancer biology, inflammation, cardiovascular disease, neurologic disorders, infectious disease, wound care, nutraceuticals and reproductive biology. Dr. Temeles has advised clients that include start-up and mid-market biotech companies, universities, pharmaceutical and medical device companies.

Dr. Temeles has scientific research experience in both the private sector and university settings. Most recently, Dr. Temeles was a research scientist and group leader in a biotechnology company, where she worked on target identification and small molecule drug discovery. Previously, she held research positions at the University of Pennsylvania, where she focused on cancer research and reproductive biology. She began her research career at Merck Sharpe and Dohme Research Laboratories, where she studied the ras oncogene. Dr. Temeles is a co-inventor on two U.S. patents.

Dr. Temeles is a 2009 graduate of Temple University Beasley School of Law and a graduate of Yale University (Ph.D., Biology) and the University of Pennsylvania (B.A., cum laude).

Areas of Practice

  • Patents
  • Intellectual Property Law


  • Pennsylvania
  • U.S. Patent and Trademark Office


  • Temple University Beasley School of Law, J.D., 2009
  • Yale University, Ph.D., Biology, 1987
  • University of Pennsylvania, B.A., cum laude, 1974


  • Duane Morris LLP
    - Associate, 2010-present
  • Fish & Richardson P.C.
    - Associate, 2010
    - Technology Specialist, 2005-2010
  • Message Pharmaceuticals
    - Project Manager, Compound Characterization, 1999-2004
    - Project Manager, Cell-Based Assay Systems, 1997-1999
    - Research Scientist, 1996-1997
  • Gen Trak, Inc.
    - Contract research position in molecular diagnostics, 1996
  • University of Pennsylvania, Department of Biology
    - Postdoctoral Fellow, 1990-1995
  • University of Pennsylvania, Department of Human Genetics
    - Research Associate, 1985-1990
  • Merck Sharp and Dohme Research Laboratories
    - Postdoctoral Researcher, 1982-1985

Professional Activities

  • Ben Franklin Technology Partners of Southeastern Pennsylvania
    - Life Sciences Technology Advisory Committee
  • University of Pennsylvania, Center for Technology Transfer
    - Triage Committee, 2004-2005

Selected Publications

  • Author, "Cannabis Patents: Patent Litigation in an Emerging U.S. Industry," Cannabis Law Journal, September 2018

  • Quoted, "Why Patent Lawyers Are Watching This Colorado Cannabis Case," The Recorder, August 8, 2018

  • Co-author, "IP Protection and the Cannabis Industry: Strategies and Trends," The Legal Intelligencer, April 2, 2018

  • Author, "Cannabis at the Cutting Edge - Patents for a New U.S. Industry," Daily Marijuana Observer, January 8, 2018

  • Author, "Cannabis: Patenting Opportunities in an Emerging U.S. Market," Cannabis Law Report, December 18, 2017

  • Co-author, "Who owns federally funded inventions?" IP Value 2012: Building and enforcing intellectual property value - An international guide for the boardroom, Intellectual Asset Magazine, 49-52 (2011)
  • Author, "Who Owns U.S-Government-Funded Inventions?," GenericsWeb newsletter InnSight, August 2011
  • Co-author, "Supreme Court Rules That Federally Funded Inventions Are Not Automatically Owned by Universities," Duane Morris Alert, June 8, 2011
  • Co-author, "Intellectual Property Law and Employees," Bloomberg Businessweek, November 16, 2010
  • Co-author, "Beyond KSR: How the Courts and the United States Patent and Trademark Office Have Decided Biotechnology and Chemistry Cases," Industrial Biotechnology, Volume 3, Number 3: 198-202 (2007)
  • Co-author, "Use of cDNA Arrays to Assess Translational Regulation of Gene Expression Reveals VHL-Mediated Repression of TNF- α Synthesis," Molecular and Cellular Biology 23: 2316-2328 (2003)
  • Co-author, "Transient Polyadenylation of a Maternal mRNA Following Fertilization of Mouse Eggs," J.Reprod. Fertil. 109: 223-8 (1997)
  • Co-author, "Temporal Pattern of IGF-I Expression During Mouse Pre-Implantation Embryogenesis," Molecular Reproduction and Development 37: 21-26 (1994)
  • Co-author, "Stage-Specific Expression of a Family of Proteins That Are Major Products of Zygotic Gene Activation in the Mouse Embryo," Developmental Biology 144: 392-404 (1991)
  • Co-author, "Modulation of Protein Expression Associated with Chemically Induced Differentiation of Neuroblastoma Cells. Fifth Symposium on Advances in Neuroblastoma Research," Prog. Clin. Biol. Res. 366: 157-163 (1991)
  • Co-author, "Immortalization of Stimulated Lymphocytes by Transfection with Oncogenic DNA. Proceedings of the First International Symposium on Biotechnology: Monoclonal Antibodies in the Treatment of Human Disease," IRL Press, McLean, Va., pp. 55-67 (1987)
  • Co-author, "Mutant ras-encoded Proteins with Altered Nucleotide Binding Exert Dominant Biological Effects," Proc. Natl. Acad. Sci. U.S.A. 83: 952-956 (1986)
  • Co-author, "Yeast and Mammalian ras Proteins Have Conserved Biochemical Properties," Nature 313: 700-703 (1985)
  • Co-author, "Expression and Characterization of ras mRNA's from Saccharomyces cerevesiae," Molecular and Cellular Biology 4: 2289-2305 (1984)
  • Co-author, "Saccharomyces cerevesiae Synthesizes Proteins Related to the p21 Gene Product of the ras Gene Found in Mammals," Molecular and Cellular Biology 4: 23-29 (1984)
  • Co-author, "TNF-α RNA stability and mRNA translation Are Not Coordinately Regulated," RNA Society of North Carolina Meeting, October 2001
  • Co-author, "TNF-α mRNA Levels Show a Biphasic Expression Pattern That Results from Both Transcriptional and Post-Transcriptional Events," American Society for Biochemistry and Molecular Biology Meeting, Boston, 2000
  • Co-author, "Analysis of CNI-1493 and Destabilizing Elements in TNF-α mRNA," American Society for Cell Biology, Washington, D.C., 1999
  • Co-author, "Specific Factors from DU-145 Prostate Carcinoma Cells That Bind cis-acting Elements in the 5'UTR of the IGF-I Receptor," American Society for Cell Biology, Washington, D.C., 1999
  • Co-author, "CNI-1493 and Destabilizing Elements in TNF-α," RNA Society Meetings, Madison, Wisconsin, 1998
  • Co-author, "Identification of Regions in the 5'UTR of the IGF-I Receptor mRNA That Bind: Proteins: An Approach to Prostate Cancer," 'Proteins that bind RNA' meetings, Avalon, New Jersey, 1998

Selected Speaking Engagements

  • Speaker, "Patenting in the Cannabis Industry," Pennsylvania IP Forum, July 19, 2018

  • Panelist, "Trademarks, Patents, and Intellectual Property in Cannabis," CannabisLearn, Philadelphia, Pennsylvania, May 1, 2018

  • Presenter, "Cannabis 102: Intellectual Property, Trademark and Branding, and Marketing," The Duane Morris Cannabis Webinar Series, February 27, 2018 (video playback)

  • Speaker, "Intellectual Property, Licensing, & Regulatory Considerations for Emerging Technologies," AIPLA Webinar, October 4, 2016
  • Moderator, "What's Hot, What's Getting Funded," 2013 New Jersey Technology Counsel Regional Commercialization Summit, Philadelphia, Pennsylvania, December 5, 2013
  • Moderator, "Making the Connection," 2012 New Jersey Technology Counsel Regional Commercialization Conference, Wilmington, Delaware, December 6, 2012
  • "Securing IP Protection in India for Methods of Treatment" panel presentation at the Pharmaceutical Consultants' Consortium meeting, Chesterbrook, Pennsylvania, September 10, 2012
  • Moderator, "IP On a Shoestring- Maximize What You Need to Do with IP," 2011 NJTC Regional Commercialization Conference, Newark, Delaware, December 8, 2011
  • "New Uses for Old Compounds," panel presentation at the Pharmaceutical Consultants' Consortium of New Jersey meeting with Neurotez,Inc., Parsippany, New Jersey, May 24, 2011
  • "IP Strategies for Immunotherapeutic Vaccines," panel presentation at the Pharmaceutical Consultants' Consortium meeting with VitaSpero,,Inc., Chesterbrook, Pennsylvania, February 15, 2011
  • "The Patent-eligibility of DNA Claims," Delco IP Forum, Media, Pennsylvania, January 13, 2011
  • "The Patent-eligibility of DNA Claims," Duane Morris IP Practice Group, Philadelphia, Pennsylvania, December 16, 2010
  • "Vanderbilt v. Icos: A Blockbuster Drug and One of the Murkiest Concepts in the Muddy Metaphysics of Patent Law," Fish & Richardson Biotech Forum, June 15, 2010
  • "Maximizing IP Value," Pharmaceutical Consultants' Consortium meeting, Immunomic Therapeutics, Chesterbrook, Pennsylvania, June 14, 2010
  • "Protecting bioengineering inventions," Introduction to BioEngineering class, Temple University, Department of Engineering, Philadelphia, Pennsylvania, February 23, 2009
  • "Takeda v. Alphapharm: Obviousness, Drug Discovery and Brown Fat," Fish & Richardson Biotech Forum, July 17, 2007
  • "IP Considerations for Startup Companies," Biotechnology Entrepreneurship Symposium, Louisiana State University Health Sciences Center and Wharton Small Business Development Center, Malvern, Pennsylvania, April 24, 2007
  • "IP Considerations for Startup Companies," Delaware Biotechnology Institute, Tech Breakfast, Newark, Delaware, April 18, 2007